Pharmacological and Non-pharmacological Approaches for the Management of Neuropathic Pain in Multiple Sclerosis.
Abstract
Multiple sclerosis is a chronic inflammatory disease that affects the central nervous system and can cause various types of pain including ongoing extremity pain, Lhermitte's phenomenon, trigeminal neuralgia, and mixed pain. Neuropathic pain is a major concern for individuals with multiple sclerosis as it is directly linked to myelin damage in the central nervous system and the management of neuropathic pain in multiple sclerosis is challenging as the options available have limited efficacy and can cause unpleasant side effects. The literature search was conducted across two databases, PubMed, and Google Scholar. Eligible studies included clinical trials, observational studies, meta-analyses, systematic reviews, and narrative reviews. The objective of this article is to provide an overview of literature on pharmacological and non-pharmacological strategies employed in the management of neuropathic pain in multiple sclerosis. Pharmacological options include cannabinoids, muscle relaxants (tizanidine, baclofen, dantrolene), anticonvulsants (benzodiazepines, gabapentin, phenytoin, carbamazepine, lamotrigine), antidepressants (duloxetine, venlafaxine, tricyclic antidepressants), opioids (naltrexone), and botulinum toxin variants, which have evidence from various clinical trials. Non-pharmacological approaches for trigeminal neuralgia may include neurosurgical methods. Non-invasive methods, physical therapy, and psychotherapy (cognitive behavioral therapy, acceptance and commitment therapy and mindfulness-based stress reduction) may be recommended for patients with neuropathic pain in multiple sclerosis. The choice of treatment depends on the severity and type of pain as well as other factors, such as patient preferences and comorbidities. There is a pressing need for healthcare professionals and researchers to prioritize the development of better strategies for managing multiple sclerosis-induced neuropathic pain.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 시술 | botulinum toxin
|
보툴리눔독소 주사 | dict | 1 | |
| 해부 | central nervous system
|
scispacy | 1 | ||
| 해부 | trigeminal
|
scispacy | 1 | ||
| 해부 | myelin
|
scispacy | 1 | ||
| 해부 | muscle relaxants
|
scispacy | 1 | ||
| 약물 | tizanidine
|
C0146011
tizanidine
|
scispacy | 1 | |
| 약물 | baclofen
|
C0004609
baclofen
|
scispacy | 1 | |
| 약물 | dantrolene
|
C0010976
dantrolene
|
scispacy | 1 | |
| 약물 | benzodiazepines
|
C0005064
Benzodiazepines
|
scispacy | 1 | |
| 약물 | gabapentin
|
C0060926
gabapentin
|
scispacy | 1 | |
| 약물 | phenytoin
|
C0031507
phenytoin
|
scispacy | 1 | |
| 약물 | carbamazepine
|
C0006949
carbamazepine
|
scispacy | 1 | |
| 약물 | lamotrigine
|
C0064636
lamotrigine
|
scispacy | 1 | |
| 약물 | antidepressants
|
C0003289
Antidepressive Agents
|
scispacy | 1 | |
| 약물 | duloxetine
|
C0245561
duloxetine
|
scispacy | 1 | |
| 약물 | venlafaxine
|
C0078569
venlafaxine
|
scispacy | 1 | |
| 약물 | naltrexone
|
C0027360
naltrexone
|
scispacy | 1 | |
| 약물 | opioids
|
scispacy | 1 | ||
| 질환 | Neuropathic Pain
|
C0027796
Neuralgia
|
scispacy | 1 | |
| 질환 | Multiple sclerosis
|
C0026769
Multiple Sclerosis
|
scispacy | 1 | |
| 질환 | chronic inflammatory disease
|
C1290886
Chronic inflammatory disorder
|
scispacy | 1 | |
| 질환 | pain
|
C0030193
Pain
|
scispacy | 1 | |
| 질환 | Lhermitte
|
scispacy | 1 | ||
| 질환 | trigeminal neuralgia
|
C0040997
Trigeminal Neuralgia
|
scispacy | 1 | |
| 질환 | myelin damage
|
scispacy | 1 | ||
| 질환 | multiple sclerosis-induced neuropathic pain
|
scispacy | 1 | ||
| 기타 | patients
|
scispacy | 1 | ||
| 기타 | patient
|
scispacy | 1 |
MeSH Terms
Humans; Multiple Sclerosis; Trigeminal Neuralgia; Acceptance and Commitment Therapy; Neuralgia; Antidepressive Agents; Anticonvulsants
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- Local therapeutic strategies for neurocutaneous dysesthesia: from capsaicin to cannabinoids.
- Comparative efficacy of intralesional therapies for keloid scars: a network meta-analysis.
- Adverse neurological events following botulinum toxin type A: A case series of post-injection seizures and paralysis.
- Decreased utilization of component separation techniques over time in complex abdominal wall reconstruction following introduction of preoperative botulinum toxin A.
- Current Perspectives on Pectoralis Minor Syndrome: A Narrative Review.